Merck Serono Australia

21 PBAC submissions on file, active 2008–2018. 57% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Cetuximab
  Oncology · Recommended · 2024other sponsor
• Cladribine
  Neurology · Not recommended · 2023other sponsor
• Follitropin alfa and lutropin alfa
  Women's health · Recommended · 2015—
• Avelumab
  Oncology · Recommended with restriction · 2022other sponsor
• Efalizumab
  Dermatology · Recommended with restriction · 2008—
• Follitropin alfa + lutropin alfa; lutropin alfa
  Women's health · Recommended · 2016—
• Follitropin alfa with lutropin alfa
  Women's health · Recommended with restriction · 2024other sponsor
• Lutropin alfa
  Women's health · Recommended with restriction · 2015—
• Sapropterin
  Metabolic · Noted · 2022other sponsor
• Sapropterin dihydrochloride
  Metabolic · Recommended with restriction · 2011—
• Somatropin
  Endocrinology · Recommended with restriction · 2023other sponsor

Therapy area mix

Activity by year

2008 (2) · 2009 (1) · 2010 (2) · 2011 (2) · 2012 (1) · 2014 (2) · 2015 (2) · 2016 (4) · 2018 (5)

Rejection patterns

Across 9 Not recommended decisions on file.

• 2×significant uncertainties in financial analysis including persistence rates
• 2×estimated significant net cost to PBS
• 2×high and uncertain cost-effectiveness
• 1×PBAC did not recommend listing based on uncertain magnitude of clinical benefit
• 1×likely high and unacceptable cost-effectiveness